Glaukos Co. (NYSE:GKOS) Shares Sold by Braidwell LP

Braidwell LP trimmed its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 7.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,876 shares of the medical instruments supplier's stock after selling 22,740 shares during the quarter. Braidwell LP owned about 0.52% of Glaukos worth $43,314,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc purchased a new position in Glaukos in the fourth quarter worth approximately $43,000. Asset Planning Inc purchased a new position in shares of Glaukos during the 4th quarter worth $90,000. Picton Mahoney Asset Management acquired a new stake in shares of Glaukos during the 4th quarter worth about $125,000. SBI Securities Co. Ltd. purchased a new position in Glaukos during the fourth quarter worth about $153,000. Finally, Smartleaf Asset Management LLC increased its position in shares of Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after acquiring an additional 807 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Transactions at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GKOS shares. Needham & Company LLC decreased their price objective on shares of Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Stifel Nicolaus lowered their price target on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Stephens cut their price objective on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Morgan Stanley lowered their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday. Finally, Truist Financial reaffirmed a "buy" rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Glaukos Stock Down 0.7 %

Shares of GKOS stock traded down $0.60 on Friday, reaching $89.94. 511,969 shares of the stock were exchanged, compared to its average volume of 680,688. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.14 billion, a price-to-earnings ratio of -31.34 and a beta of 0.83. The business's 50 day moving average price is $94.87 and its 200 day moving average price is $127.35.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business's quarterly revenue was up 24.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.70) EPS. As a group, sell-side analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.